Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

acute graft versus host disease - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

acute graft versus host disease

MONDO:0020546

Also known as:GVHD, acuteacute graft vs. host diseasefulminant graft versus host disease

Find Clinical TrialsTrials

Overview

A syndrome of immunologically mediated tissue damage that may occur following an allogeneic transplant, usually affecting the skin, liver, and GI tract. The onset is usually within one hundred days of transplantation or immunologic manipulation.

Treatments1 FDA approved, newest 2024

Clinical Trials17 registered · 7 recruiting

Diagnosis

Biomarker and diagnostic research for acute graft versus host disease has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for acute graft versus host disease, including remestemcel-L-rknd (ryoncil, approved 2024). An additional 10 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

17 clinical trials registered, 7 recruiting. Interventions under study include drug therapy, other interventions, procedural interventions, and biologic therapy. Pipeline includes 3 PHASE3, 5 PHASE2, 5 PHASE1. Research is primarily sponsored by academic and government institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT05921305](https://clinicaltrials.gov/study/NCT05921305)

Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 2:58 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:99920

GARD

Genetic and Rare Diseases Info Center

GARD:6544

Questions for Your Care Team

→What are the benefits and potential side effects of ryoncil for managing acute graft versus host disease?
→Are any of the 17 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
allogeneic-unrelated, CD4+ T cells transduced with lentiviral vector encoding full-length human interleukin-10 gene and a truncated (non-signaling) form of the human nerve growth factor receptor	allogeneic-unrelated, CD4+ T cells transduced with lentiviral vector encoding full-length human interleukin-10 gene and a truncated (non-signaling) form of the human nerve growth factor receptor	Tr1X, Inc.	2025	—	Designated
tregalizumab	tregalizumab	T-Balance Therapeutics GmbH	2023	—	Designated
Teduglutide	Teduglutide	9 Meters Biopharma Inc.	2020	—	Designated
defibrotide	defibrotide	Jazz Pharmaceuticals Ireland Limited	2020	—	Withdrawn
acazicolcept	acazicolcept	Alpine Immune Sciences	2020	—	Designated
recombinant human interleukin 22-human immunoglobulin Fc fusion protein	recombinant human interleukin 22-human immunoglobulin Fc fusion protein	Evive Biotechnology (Shanghai) Ltd.	2019	—	Designated
itolizumab	itolizumab	Biocon Limited	2019	—	Designated
Allogeneic mesenchymoangioblast-derived mesenchymal stem cells	Allogeneic mesenchymoangioblast-derived mesenchymal stem cells	Cynata Therapeutics Limited	2018	—	Designated
Human alpha-1-antitrypsin	Human alpha-1-antitrypsin	Paul Maher, MD	2017	—	Designated
Recombinant human monoclonal antibody against human complement component C5a	Recombinant human monoclonal antibody against human complement component C5a	Alexion Pharmaceuticals, Inc.	2016	—	Withdrawn

Research Type	Count	% of Total
Laboratory research	55	22%
Clinical study results	54	21%
Research summaries	51	20%
Disease patterns and progression	42	16%
Testing and diagnosis research	26	10%
New treatment approaches	13	5%
Patient case studies	12	5%
Other research	2	1%

Kisho

acute graft versus host disease

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Acute Graft-Versus-Host Disease After Deceased-Donor Liver Transplantation: A Case Report.

acute graft versus host disease

Overview

Diagnosis

Treatment

Approved Therapies

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Orphan Drug Designations

Clinical Trials

Recent Publications

Latest News & Developments

Acute Graft-Versus-Host Disease After Deceased-Donor Liver Transplantation: A Case Report.